Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a top competitor in the regenerative medicine market, offering a diverse portfolio of advanced wound care and sports medicine products. The recent release of 4Q25 financial results and FY26 guidance show strong growth potential, driven by increased demand for their products and high-teens adjusted EBITDA margins. The company's expanding product portfolio and its focus on addressing unmet needs in the market, such as their highly versatile PuraPly product and the upcoming return of Dermagraft, further support a positive outlook for the stock.

Bears say

Organogenesis Holdings is facing negative headwinds in its advanced wound care segment, including slower-than-expected growth in PuraPly, pricing pressures on its amniotic products from Medicare Part B, and challenges from competitors. Additionally, changes to reimbursement structures are leading to confusion and a freeze in product utilization by clinicians, which could negatively impact the company's financials. Despite its potential for growth, the company's outlook is hindered by these fundamental factors.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.